Cramp Bark

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph exists for Viburnum opulus

ESCOP

• No ESCOP monograph exists for Viburnum opulus

EMA/HMPC

• No EMA/HMPC monograph exists for Viburnum opulus

British Herbal Pharmacopoeia (BHP)

• Cramp bark is listed in the British Herbal Pharmacopoeia
• Indications: Muscular cramps, uterine muscle spasm, ovarian pain
• Actions: Antispasmodic, anti-inflammatory, nervine, astringent
• This represents the highest level of formal pharmacopoeial recognition the herb currently holds in Western regulatory systems

American Herbal Pharmacopoeia (AHP)

• The AHP has published a quality control and therapeutic monograph for cramp bark (Viburnum opulus)
• Provides analytical methodologies for differentiating V. opulus from other Viburnum species (using HPTLC: lack of amentoflavone coupled with strong catechin presence distinguishes V. opulus)
• Describes the herb as “one of the most important herbs used for female reproductive health in Western herbal traditions”

United States Pharmacopoeia / National Formulary (Historical)

• USP listing: The bark was made official in the U.S. Pharmacopoeia in 1894
• National Formulary: Included from 1916, in the form of a Fluid Extract, Compound Tincture, and Compound Elixir
• Current status: No longer listed in the USP; available as a dietary supplement

State Pharmacopoeia of the USSR (Historical)

• The bark was included in the State Pharmacopoeia of the USSR in 1952

Agreement/Disagreement Between Bodies

• Striking absence: No major European regulatory body (Commission E, ESCOP, EMA) has adopted a monograph for cramp bark, despite its widespread traditional use and pharmacopoeial listing in the BHP and AHP
• Traditional authority outstrips regulatory validation: Cramp bark is universally prescribed by Western herbalists for dysmenorrhea, yet has no formal European regulatory endorsement
• AHP is the most thorough: The American Herbal Pharmacopoeia monograph provides the most detailed modern quality-control and therapeutic review

Conditions Treated

Primary (Traditional, Pharmacologically Supported)

• Dysmenorrhea (menstrual cramps): The defining traditional indication; the plant’s common name reflects this use. Both viopudial and scopoletin have demonstrated uterine smooth muscle relaxant activity in vitro
• Uterine spasm and cramping: General uterine antispasmodic, classically indicated for cramps that radiate into the thighs (a distinguishing feature in traditional differential prescribing between V. opulus and V. prunifolium)
• Ovarian pain: Listed in the British Herbal Pharmacopoeia

Secondary (Traditional, Less Studied)

• Gastrointestinal spasm: Smooth muscle antispasmodic action extends beyond the uterus; cramp bark has been used for intestinal colic, stomach cramps, and irritable bowel cramping
• Threatened miscarriage (historical): One of the traditional uses cited by Eclectic physicians and in the British herbal tradition; both Viburnum species (V. opulus and V. prunifolium) have a long history of use to “prevent miscarriage.” This use is entirely based on traditional authority and has no modern clinical evidence. Not recommended without medical supervision
• General smooth muscle relaxant: Skeletal muscle cramping, leg cramps, back spasm; used as a broad antispasmodic in Western herbal practice
• Bladder spasm: Listed by Eclectic physicians for urinary tract cramping
• Heart palpitations: Historical Eclectic use, likely related to smooth muscle/autonomic effects

Investigated but Very Limited

• Endometriosis: A 2016 animal study (Saltan et al.) demonstrated that V. opulus fruit extracts reduced endometriotic implant volume in a rat model of surgically induced endometriosis, with reductions in TNF-alpha, VEGF, and IL-6 levels. This is a single preclinical study and cannot support clinical recommendations [PMID: 27647013]
• Gastroprotection: A 2006 study found that V. opulus proanthocyanidins protected against stress-induced gastrointestinal mucosal damage in rats [PMID: 17218766]

Mechanism of Action

Key Bioactive Compounds

Primary Mechanism: Musculotropic Spasmolysis

Cramp bark exerts its antispasmodic action through a direct musculotropic mechanism — that is, it acts directly on smooth muscle tissue rather than through nervous system pathways. This distinguishes it from neurotropic antispasmodics.

The Viopudial-Scopoletin Dual Mechanism

Both viopudial and scopoletin have been determined to be responsible for the uterine relaxant activity of V. opulus. Their roles are complementary:

1. Viopudial: A coumarin compound unique to V. opulus (not found in the related V. prunifolium / black haw). It was isolated and characterized by Nicholson, Darby, and Jarboe (1972). Viopudial produces both hypotensive effects (via peripheral vasodilation from arterial smooth muscle relaxation) and smooth muscle antispasmodic activity. Its presence in V. opulus but absence in V. prunifolium may explain why in vitro studies found V. opulus extract to be approximately four times more active than V. prunifolium extract at relaxing uterine contractions
2. Scopoletin: A coumarin shared by both Viburnum species. Identified as an antispasmodic component by Jarboe et al. (1967). Scopoletin is described as the “major constituent responsible for antispasmodic action” in some references, though viopudial appears to provide additional potency unique to cramp bark

Mechanistic Cascade

1. Viopudial and scopoletin act directly on smooth muscle cells (musculotropic, not neurotropic)
2. Reduction in tonic and phasic smooth muscle contraction
3. Uterine relaxation — reduction in both intensity and frequency of myometrial contractions
4. Peripheral vasodilation (arterial smooth muscle relaxation) producing mild hypotensive effects
5. Extension of spasmolytic activity to gastrointestinal, urinary, and bronchial smooth muscle

Additional Activities

• Anti-inflammatory: Salicylates and phenolic acids provide mild cyclooxygenase inhibition and prostaglandin modulation
• Antioxidant: Proanthocyanidins and phenolic acids contribute antioxidant and free-radical scavenging activity
• Astringent: Tannin content provides traditional astringent effects on mucosal tissues
• Nervine: Valerianic acid (also found in valerian root) may contribute mild nervine/sedative effects

Critical Assessment

• The pharmacological rationale for cramp bark’s antispasmodic activity is coherent and well-characterized at the compound level, particularly for viopudial and scopoletin
• However, the foundational pharmacological work dates to the 1960s and 1970s and has received virtually no modern replication or extension
• No human pharmacokinetic studies exist for viopudial or scopoletin from Viburnum sources
• The relationship between traditional doses of bark preparations and the tissue concentrations needed for spasmolytic activity has never been established

Clinical Evidence Summary

The Central Problem: Near-Absence of Clinical Trials

Cramp bark is one of the most prescribed herbs in Western herbal practice for dysmenorrhea, yet it has virtually no modern clinical trial evidence. This represents one of the most pronounced gaps between traditional reputation and evidence-based validation in phytotherapy.

Foundational Pharmacological Studies

The pharmacological basis rests on a small cluster of studies from a single research group in the 1960s-1970s:

Preclinical Studies (Modern)

Clinical Trials

Honest Assessment of the Evidence

• No randomized, double-blind, placebo-controlled trial of cramp bark at herbal (non-homeopathic) doses exists for any indication
• The pharmacological foundation, while coherent, dates to the 1960s-1970s and has not been replicated with modern methodologies
• The single registered clinical trial used a homeopathic preparation (3X dilution), which does not validate the traditional herbal use at standard doses
• No dose-response studies in humans exist
• No head-to-head comparisons with NSAIDs or other conventional treatments for dysmenorrhea have been conducted
• The herb’s continued popularity rests entirely on traditional authority, clinical experience of herbalists, and pharmacological plausibility — not on clinical trial evidence
• This evidence gap is not unique to cramp bark (many traditional Western herbs lack clinical trials), but it is particularly striking given the herb’s ubiquity in herbal practice and its clear pharmacological rationale, which would make it an excellent candidate for clinical investigation

Safety Profile

Important Distinction: Bark vs. Berries

The medicinal part used is the bark, not the berries (fruits). This distinction is critical for safety:

• Bark: No known toxicity. The American Herbal Pharmacopoeia states that there is “no known contraindication or toxicity” associated with cramp bark
• Berries (raw): Contain oxalates and are considered mildly toxic when consumed raw in large amounts; may cause digestive upset. Berries are edible when cooked (traditional in Eastern European cuisine as “kalyna”) but are not the medicinal part

Contraindications

• Known hypersensitivity to Viburnum opulus or Adoxaceae
• Kidney stones: Theoretical concern due to oxalate content, though this applies primarily to the berries rather than the bark
• Aspirin/salicylate sensitivity: The bark contains salicylates; caution in individuals with salicylate allergy

Drug Interactions

• No significant drug interactions have been documented in the literature
• Theoretical considerations:
  • Anticoagulants and antiplatelet agents: The bark contains coumarins (scopoletin, viopudial) and salicylates. Some sources recommend caution with concurrent warfarin, aspirin, or NSAID use, though no clinical interaction reports exist
  • Antihypertensives: Viopudial has demonstrated hypotensive activity in animal models; additive blood-pressure-lowering effects are theoretically possible but undocumented in humans
• The clinical significance of these theoretical interactions is unknown due to the absence of pharmacokinetic studies

Side Effects

• At standard herbal doses, no side effects or adverse events have been reported in the available literature
• The herb is generally regarded as very well tolerated
• Mild gastrointestinal upset is theoretically possible (tannin content) but not documented

Pregnancy and Lactation

• Pregnancy: Cramp bark has been traditionally used in pregnancy to prevent threatened miscarriage and relieve uterine cramping. However, no modern safety data from controlled studies exist. Given its uterine relaxant activity, use in pregnancy should only occur under the guidance of a qualified healthcare provider
• Lactation: Insufficient data. No adverse effects reported, but no safety studies have been conducted
• Pregnancy category: C (risk cannot be ruled out; no adequate human data)

Toxicological Data

• No formal toxicological studies of cramp bark have been conducted
• The long history of traditional use without reports of serious adverse events provides some reassurance, but absence of evidence is not evidence of absence
• The American Herbal Pharmacopoeia assessment notes no known toxicity

Clinical Dosage

Recommended Forms and Doses

Historical Preparation (Eclectic)

• A decoction was prepared by macerating two ounces of bark in a quart of hot water, expressing, and evaporating to half a pint; one fluid ounce was given three or four times daily

Key Considerations

• No standardized extract exists with clinical validation
• No dose-finding studies have been conducted
• All dosage recommendations are based on traditional use and clinical experience of herbalists, not on clinical trial data
• Onset: Traditionally considered rapid-acting for acute cramps (within 15-30 minutes for tincture); used both acutely and as a course of treatment
• Duration: May be taken throughout the menstrual cycle or specifically in the days surrounding menstruation; no established maximum duration of use
• Combination use: Frequently combined with other antispasmodic and women’s health herbs, including valerian (Valeriana officinalis), black haw (Viburnum prunifolium), ginger (Zingiber officinale), and raspberry leaf (Rubus idaeus)

Sources

Key Pharmacological Studies

• Jarboe CH, Schmidt CM, Nicholson JA, Zirvi KA. Uterine relaxant properties of Viburnum. Nature. 1966;212:837. PMID: 5988219
• Jarboe CH, Zirvi KA, Nicholson JA, Schmidt CM. Scopoletin, an antispasmodic component of Viburnum opulus and prunifolium. J Med Chem. 1967;10(3):488-489. PMID: 22185161
• Nicholson JA, Darby TD, Jarboe CH. Viopudial, a hypotensive and smooth muscle antispasmodic from Viburnum opulus. Proc Soc Exp Biol Med. 1972;140(2):457-461. PMID: 5037580

Modern Preclinical Studies

• Zayachkivska OS, Gzhegotsky MR, Terletska OI, et al. Influence of Viburnum opulus proanthocyanidins on stress-induced gastrointestinal mucosal damage. J Physiol Pharmacol. 2006;57 Suppl 5:155-167. PMID: 17218766
• Saltan G, Suntar I, Ozbilgin S, et al. Viburnum opulus L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis. J Ethnopharmacol. 2016;193:450-455. PMID: 27647013

Review Articles

• Kajszczak D, Zaklos-Szyda M, Podsedek A. Viburnum opulus L. — A review of phytochemistry and biological effects. Nutrients. 2020;12(11):3398. PMID: 33167421

Pharmacopoeial and Monograph Sources

• British Herbal Pharmacopoeia. British Herbal Medicine Association.
• American Herbal Pharmacopoeia. Cramp Bark, Viburnum opulus: Analytical, Quality Control, and Therapeutic Monograph. AHP, 2000.
• King’s American Dispensatory (Eclectic): Viburnum Opulus

Connections

• Compare with Vitex / Chasteberry — both are premier Western herbs for women’s health, but Vitex has strong clinical trial evidence and an EMA monograph while cramp bark has virtually none; Vitex works through dopamine D2 receptor agonism (hormonal pathway) while cramp bark works through direct musculotropic spasmolysis
• Compare with Raspberry Leaf — another traditional uterine herb with a similar evidence gap; raspberry leaf has an EMA traditional-use monograph (for menstrual cramps, not pregnancy use), while cramp bark lacks even that level of regulatory recognition
• Compare with Dong Quai — both are traditional antispasmodics for dysmenorrhea with weak evidence bases; dong quai’s EMA monograph was explicitly rejected, while cramp bark was simply never submitted; dong quai has significant anticoagulant drug interactions, while cramp bark’s interaction profile appears more benign
• Compare with Black Cohosh — another prominent women’s health herb in Western herbalism with a different indication focus (menopause vs. menstrual cramps) and substantially stronger clinical evidence
• Compare with Valerian — cramp bark contains valerianic acid (also found in valerian root); both herbs have antispasmodic properties, but valerian acts primarily through GABAergic mechanisms in the central nervous system, while cramp bark acts peripherally on smooth muscle
• The closely related black haw (Viburnum prunifolium) is used interchangeably by many herbalists, but V. opulus contains viopudial (absent in V. prunifolium), which may account for its greater in vitro potency for uterine relaxation